Taiho Pharmaceutical Company Limited

Osaka Bioscience Institute

Other

Maruha Corporation

Japan Science and Technology Corporation

Japan Science and Technology Agency

Riken Corporation

Oriental Yeast Co., Ltd.

National Center of Neurology and Psychiatry

University of Tsukuba

Yoshihiro Urade

Hiroshi Oda

Nobuyuki Sato

Kosuke Seiki

Naomi Eguchi

Keiko Yamane

Makoto Kitade

Kazuhiko Shigeno

Hiroshi Nakajima

Katsunao Tanaka

Kosuke Aritake

Masazumi Nishikawa

Yoshio Uehara

Masashi Miyano

Naoki Hayashi

Shin'ichi Takeda

Hiroshi Takenaka

Shinichi Aoki

Hiroyoshi Yamanaka

Osamu Hayaishi

Fumitaka Saji

Satoru Takeda

Teruo Inoue

Yasushi Fujitani

Ikuko Mori

Hiroaki Kitayama

Nobuhito Hirawa

Masako Taniike

Yo Sato

Yutaka Eguchi

Takashi Inui

Hiroya Nakau

Mitsuhito Mase

Yasuhiko Shiina

Yousuke Okano

Masaki Yamamoto

Toshihiko Maruyama

Shinya Kamauchi

Akinori Nakamura

Sawako Hyo

Ryo Kawata

Yoshiki Tanaka

Michinori Togawa

Tsuyoshi Inoue

Yasushi Kai

Shigehiro Kinugasa

Hiroyoshi Matsumura

Daisuke Irikura

Takashi Kumasaka

SHIN'ICHI Takeda

The present invention provides a piperidine compound represented by Formula (I) (wherein X, X, X, A, B and N are as defined in the Description); or a salt thereof.

Prostaglandin D synthase inhibitory piperidine compounds

This invention relates to a piperazine compound represented by Formula (I), wherein

Piperazine compound capable of inhibiting prostaglandin D synthase

This invention relates to a piperazine compound represented by Formula (I), 

The present invention provides a piperazine compound represented by Formula (I) or a salt thereof, wherein

Piperazine compound having a PGDS inhibitory effect

Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9&#x3b1;-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as 'Tetranor-PGDM', hereinbelow) in a sample isolated from a subject.

Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases

A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.

Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease

The present invention provides a benzimidazole compound represented by Formula (I) wherein Xis oxygen or carbonyl, and Ris a furan ring having 1 to 3 substituents or a pyrrole ring that may have 1 to 3 substituents; excluding compounds represented by Formula (I) wherein at least one of the substituents is a phosphoric acid group or a phosphoric ester group; or a salt thereof. The benzimidazole compound or salt thereof has excellent prostaglandin synthase inhibitory activity, and is useful as an agent for preventing and/or treating diseases in which prostaglandin D2 or metabolites thereof participates, such as allergic and inflammatory diseases, and as inhibitor for the exacerbation of Alzheimer's disease or cerebral damage.

Benzoimidazole compound capable of inhibiting prostaglandin D synthetase

A method of designing an anti-allergic agent, sleep controlling agent, anti-obestic agent and remedy for brain injury acting via the inhibition of biosynthesis of prostaglandin D. Crystal of a complex of human origin hematopoietic prostaglandin D synthase, glutathione, and a substrate analog or an inhibitor, etc are prepared and the three-dimensional structural coordinate of each atom in the complex is determined by X-ray crystal analysis.

Three-dimensional structure of prostaglandin D synthase and utilization thereof

Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.

Method for predicting pregnancy-induced hypertension

The present invention relates to methods for differentiating demential diseases comprising measuring the concentration of human lipocalin-type prostaglandin D synthase in a sample of a body fluid collected from a subject and kits for differentiating demential diseases comprising an antibody specific to human lipocalin-type prostaglandin D synthase.

Methods to facilitate diagnosis of normal pressure hydrocephalus

An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.

Method for treating myolytic disease and method for screening antimyolytic agent

The present application provides a human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin Dsynthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin Dsynthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene. The present application also provides a method of using the transgenic animal for testing in vivo activity of a candidate for anti-allergy medicines, sleep-controlling substances and candidates for anti-obesity.

Animal with the mass expression of human gene and test method by using the animal

The present invention relates to a method of detection of an early-stage renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and comparing the determined concentration with a reference value set by determining the concentrations of human lipocalin-type prostaglandin D synthase in body fluid samples taken from healthy subjects; and a method of disease state management for a renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and evaluating the glomerular filtration ability of the subject from the determined concentration.

Method of detection and disease state management for renal diseases

The present invention provides a method for predicting restenosis following coronary intervention by measuring human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample. More particularly, this method comprises measuring the L-PGDS concentration in the sample and predicting restenosis following coronary intervention by using a change therein as an indicator.

Method for restenosis following coronary vessel intervention

The invention relates to a monoclonal antibody specifically recognizing lipocalin-type prostaglandin D synthase (L-PGDS), a hybridoma producing the monoclonal antibody, methods for detection of L-PGDS or diseases by the monoclonal antibody, and a kit for detection of L-PGDS by the monoclonal antibody. According to the invention, there is provided a monoclonal antibody specific to L-PGDS.

Prostaglandin D synthase-specific monoclonal antibody

Growing community of inventors

Kyoto, Japan

Yoshihiro Urade